Literature DB >> 22521986

[Low circulating anti-Müllerian hormone and normal follicle stimulating hormone levels: which prognosis in an IVF program?].

V Grzegorczyk-Martin1, M Khrouf, S Bringer-Deutsch, J-M Mayenga, O Kulski, P Cohen-Bacrie, J-L Benaim, J Belaisch-Allart.   

Abstract

OBJECTIVE: To evaluate the results of controlled ovarian hyperstimulation (COH) for IVF in patients with low anti-Müllerian hormone (AMH) and normal basal follicle stimulating hormone (FSH) and Estradiol levels (≤50 pg/mL). PATIENTS AND METHODS: A retrospective cohort study including 704 patients for whom AMH and FSH levels (measured between days 3 and 5 of the menstrual cycle) were available, is performed in the IVF center at the Sèvres Hospital (France). Three groups are designed and analyzed: group 1 with AMH less or equal to 2 ng/mL and FSH less or equal to 10 mUI/mL (study group), Group 2 with AMH greater than 2 ng/mL and FSH less or equal to 10 mUI/mL (control group) and Group 3 with AMH less or equal to 2 ng/mL and FSH greater than 10 mUI/mL (group with decreased ovarian reserve).
RESULTS: IVF outcome for patients from the study group is significantly worse than that of the second but not than that of the third group. In the first group, the number of retrieved oocytes, the number of total obtained embryos, the clinical pregnancy rate and the live birth rate are significantly lower than in the second group; moreover, there are more cancelled cycles because of poor response in the first group. There is no difference with the third group. DISCUSSION AND
CONCLUSIONS: This study shows that women with a low baseline AMH have a similar response to COH to the poor responders patients with a decreased ovarian reserve revealed by an elevated FSH level. Thus, when a woman undergoing IVF cycle presents a low AMH, she might be considered as a poor responder patient regardless of the FSH level and, although the clinical pregnancy rate is not so disappointing (18%), the couple should be informed of a higher risk of cycle cancellation.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521986     DOI: 10.1016/j.gyobfe.2012.02.001

Source DB:  PubMed          Journal:  Gynecol Obstet Fertil        ISSN: 1297-9589


  6 in total

Review 1.  Anti-müllerian hormone as a predictor for live birth among women undergoing IVF/ICSI in different age groups: an update of systematic review and meta-analysis.

Authors:  Ni-Jie Li; Qing-Yun Yao; Xiao-Qiong Yuan; Yong Huang; Yu-Feng Li
Journal:  Arch Gynecol Obstet       Date:  2022-07-30       Impact factor: 2.493

2.  An in silico model using prognostic genetic factors for ovarian response in controlled ovarian stimulation: A systematic review.

Authors:  B S Eisele; G C Villalba Silva; C Bessow; R Donato; V K Genro; J S Cunha-Filho
Journal:  J Assist Reprod Genet       Date:  2021-03-31       Impact factor: 3.357

3.  External validation of anti-Müllerian hormone based prediction of live birth in assisted conception.

Authors:  Amani Khader; Suzanne M Lloyd; Alex McConnachie; Richard Fleming; Valentina Grisendi; Antonio La Marca; Scott M Nelson
Journal:  J Ovarian Res       Date:  2013-01-07       Impact factor: 4.234

4.  Discrepancies between Antimullerian Hormone and Follicle Stimulating Hormone in Assisted Reproduction.

Authors:  Munawar Hussain; David Cahill; Valentine Akande; Uma Gordon
Journal:  Obstet Gynecol Int       Date:  2013-12-18

5.  Does loop electrosurgical excision procedure of the uterine cervix affect anti-Müllerian hormone levels?

Authors:  Martha M Sklavos; Cassandra N Spracklen; Audrey F Saftlas; Ligia A Pinto
Journal:  Biomed Res Int       Date:  2014-02-23       Impact factor: 3.411

6.  Predictive parameters of arteriovenous fistula maturation in patients with end-stage renal disease.

Authors:  Muhammad A Siddiqui; Suhel Ashraff; Derek Santos; Robert Rush; Thomas Carline; Zahid Raza
Journal:  Kidney Res Clin Pract       Date:  2018-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.